Global Health Research
The overarching focus of the work in Dr. Kirkpatrick’s lab and in the Vaccine Testing Center is the concentration on Infectious Diseases of global significance. Our two main areas of interest are vaccine development and infectious disease immunology. We are also interested in characterizing how the human host responds immunologically to clinically important infectious agents and vaccines. The goal of this work is to gain a better understanding of immunologic responses to vaccines as well as natural infection.
Ongoing Clinical Research Trials
- A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Vaccine
Exploration of the Biologic Basis for the Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose of Live Oral Cholera Vaccine Candidate PXVX0200 CVD 103-HgR Strain, in Preventing Cholera following Challenge with Vibrio Cholerae O1 El Tor Inaba 10 Days or 3 Months after Vaccination
Previous Clinical Research Trials
- Typhoid Fever
- Cryptosporidium infections
- Campylobacter jejuni infections
BD Kirkpatrick, Rasidul Haque, Priya Duggal, Dinesh Mondal, Cathy Larsson, Kristine Peterson, Jasmin Akter, Lauren Lockhart, Salwa Khan, William A Petri, Jr. Association of Cryptosporidium Infection with HLA Class I and II Alleles. Journal Infectious Diseases 2008; 197: 474-478.
Lindow JC, Poly F, Tribble DR, Guerry P, Carmolli MP, Baqar S, Porter CK, Pierce KK, Darsley MJ, Sadigh KS, Dill EA; Campylobacter Study Team, Kirkpatrick BD. Caught in the act: in vivo development of macrolide resistance to Campylobacter jejuni infection. J Clin Microbiol. 2010 Aug;48(8):3012-5.
Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, Larsson CJ, Martinez T, Feller A, Ventrone CH, Sack DA, DeNearing B, Fingar A, Pierce K, Dill EA, Schwartz HI, Beardsworth EE, Kilonzo B, May JP, Lam W, Upton A, Budhram R, Kirkpatrick BD. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units. Vaccine. 2010 Apr 30;28(20):3602-8.
Carmolli M, Duggal P, Haque R, Lindow J, Mondal D, Petri WA Jr, Mourningstar P, Larsson CJ, Sreenivasan M, Khan S, Kirkpatrick BD. Deficient serum mannose-binding lectin levels and MBL2 polymorphisms increase the risk of single and recurrent Cryptosporidium infections in young children. J Infect Dis. 2009 Nov 15;200(10):1540-7.
Last modified August 25 2014 09:04 AM